Advertisement

Index by Author

April 1997; 46 (4)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. Abumrad, N N

    • Renal glucose production during insulin-induced hypoglycemia. Diabetes April 1997 46:643-646; doi:10.2337/diabetes.46.4.643

  2. Acheson, A

    • Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Diabetes April 1997 46:647-652; doi:10.2337/diabetes.46.4.647

  3. Adam, H

    • Nitric oxide and ocular blood flow in patients with IDDM. Diabetes April 1997 46:653-658; doi:10.2337/diabetes.46.4.653

  4. Akerblom, H K

    • Glutamate decarboxylase-reactive peripheral blood lymphocytes from patients with IDDM express gut-specific homing receptor alpha4beta7-integrin. Diabetes April 1997 46:583-588; doi:10.2337/diabetes.46.4.583

  5. Almind, K

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  6. Andres, R

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  7. Appleton, M

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

B

  1. Bain, R P

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  2. Bain, S C

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

  3. Baird, J D

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

  4. Baker, J E

    • Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes April 1997 46:637-642; doi:10.2337/diabetes.46.4.637

  5. Barazi, M

    • Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes April 1997 46:659-664; doi:10.2337/diabetes.46.4.659

  6. Barrett-Connor, E L

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  7. Basdevant, A

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  8. Baxter, A G

    • Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes April 1997 46:572-582; doi:10.2337/diabetes.46.4.572

  9. Becker, D J

    • Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes April 1997 46:665-670; doi:10.2337/diabetes.46.4.665

  10. Bell, G I

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720
    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  11. Berger, W

    • Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes April 1997 46:622-631; doi:10.2337/diabetes.46.4.622

  12. Berling, K

    • Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes April 1997 46:565-571; doi:10.2337/diabetes.46.4.565

  13. Bilbao, J R

    • Anti-insulin activity in normal newborn cord-blood serum: absence of IgG-mediated insulin binding. Diabetes April 1997 46:713-716; doi:10.2337/diabetes.46.4.713

  14. Böhm, B O

    • Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes April 1997 46:565-571; doi:10.2337/diabetes.46.4.565

  15. Breiteneder, H

    • Nitric oxide and ocular blood flow in patients with IDDM. Diabetes April 1997 46:653-658; doi:10.2337/diabetes.46.4.653

  16. Bulamn, M P

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

C

  1. Calcutt, N A

    • Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Diabetes April 1997 46:647-652; doi:10.2337/diabetes.46.4.647

  2. Calvo, B

    • Anti-insulin activity in normal newborn cord-blood serum: absence of IgG-mediated insulin binding. Diabetes April 1997 46:713-716; doi:10.2337/diabetes.46.4.713

  3. Castaño, L

    • Anti-insulin activity in normal newborn cord-blood serum: absence of IgG-mediated insulin binding. Diabetes April 1997 46:713-716; doi:10.2337/diabetes.46.4.713

  4. Cersosimo, E

    • Renal glucose production during insulin-induced hypoglycemia. Diabetes April 1997 46:643-646; doi:10.2337/diabetes.46.4.643

  5. Chance, R E

    • Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model. Diabetes April 1997 46:548-556; doi:10.2337/diabetes.46.4.548

  6. Chen, V J

    • Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes April 1997 46:637-642; doi:10.2337/diabetes.46.4.637

  7. Cheung, R K

    • Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk-based IDDM prevention trial. Diabetes April 1997 46:557-564; doi:10.2337/diabetes.46.4.557

  8. Clément, K

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  9. Cloutier, H E

    • Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats: dose, timing, early effect on islet area, and switch in infiltrate from Th1 to Th2 cells. Diabetes April 1997 46:589-598; doi:10.2337/diabetes.46.4.589

  10. Collins, V R

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  11. Cooke, A

    • alpha-Cell neogenesis in an animal model of IDDM. Diabetes April 1997 46:599-606; doi:10.2337/diabetes.46.4.599

  12. Craven, P A

    • Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes April 1997 46:671-681; doi:10.2337/diabetes.46.4.671

  13. Cusick, T S

    • Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes April 1997 46:637-642; doi:10.2337/diabetes.46.4.637

  14. Cusin, I

    • Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes April 1997 46:717-719; doi:10.2337/diabetes.46.4.717

D

  1. Davies, J C

    • Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model. Diabetes April 1997 46:548-556; doi:10.2337/diabetes.46.4.548

  2. Demenais, F

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  3. Denny, P

    • Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes April 1997 46:695-700; doi:10.2337/diabetes.46.4.695

  4. DeRubertis, F R

    • Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes April 1997 46:671-681; doi:10.2337/diabetes.46.4.671

  5. DiMarchi, R D

    • Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model. Diabetes April 1997 46:548-556; doi:10.2337/diabetes.46.4.548

  6. Dina, C

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  7. Ding, W G

    • Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes April 1997 46:615-621; doi:10.2337/diabetes.46.4.615

  8. DiStefano, P S

    • Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Diabetes April 1997 46:647-652; doi:10.2337/diabetes.46.4.647

  9. Dominguez, L J

    • Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes April 1997 46:659-664; doi:10.2337/diabetes.46.4.659

  10. Dosch, H M

    • Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk-based IDDM prevention trial. Diabetes April 1997 46:557-564; doi:10.2337/diabetes.46.4.557

  11. Dowse, G K

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  12. Dronsfield, M J

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

  13. Dussoix, P

    • Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes April 1997 46:622-631; doi:10.2337/diabetes.46.4.622

E

  1. Echwald, S M

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  2. Edelstein, S L

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  3. Edlund, H

    • alpha-Cell neogenesis in an animal model of IDDM. Diabetes April 1997 46:599-606; doi:10.2337/diabetes.46.4.599

  4. Eiberg, H

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  5. Eichler, H G

    • Nitric oxide and ocular blood flow in patients with IDDM. Diabetes April 1997 46:653-658; doi:10.2337/diabetes.46.4.653

  6. Ellard, S

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

F

  1. Fasching, P

    • Nitric oxide and ocular blood flow in patients with IDDM. Diabetes April 1997 46:653-658; doi:10.2337/diabetes.46.4.653

  2. Felder, J

    • Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes April 1997 46:671-681; doi:10.2337/diabetes.46.4.671

  3. Ferber, W

    • Nitric oxide and ocular blood flow in patients with IDDM. Diabetes April 1997 46:653-658; doi:10.2337/diabetes.46.4.653

  4. Findl, O

    • Nitric oxide and ocular blood flow in patients with IDDM. Diabetes April 1997 46:653-658; doi:10.2337/diabetes.46.4.653

  5. Forrest, K Y

    • Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes April 1997 46:665-670; doi:10.2337/diabetes.46.4.665

  6. Frayling, T M

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

  7. Fridberg, M

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  8. Froguel, P

    • Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes April 1997 46:622-631; doi:10.2337/diabetes.46.4.622
    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  9. Fulford, T

    • alpha-Cell neogenesis in an animal model of IDDM. Diabetes April 1997 46:599-606; doi:10.2337/diabetes.46.4.599

G

  1. Godfrey, D I

    • Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes April 1997 46:572-582; doi:10.2337/diabetes.46.4.572

  2. Gottlieb, A

    • Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes April 1997 46:632-636; doi:10.2337/diabetes.46.4.632

  3. Goy, J V

    • Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes April 1997 46:695-700; doi:10.2337/diabetes.46.4.695

  4. Gromada, J

    • Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes April 1997 46:615-621; doi:10.2337/diabetes.46.4.615

  5. Gu, D

    • alpha-Cell neogenesis in an animal model of IDDM. Diabetes April 1997 46:599-606; doi:10.2337/diabetes.46.4.599

  6. Guy-Grand, B

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

H

  1. Haffner, S M

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  2. Hager, J

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  3. Hamman, R F

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  4. Hammond, K J

    • Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes April 1997 46:572-582; doi:10.2337/diabetes.46.4.572

  5. Hammond-McKibben, D

    • Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk-based IDDM prevention trial. Diabetes April 1997 46:557-564; doi:10.2337/diabetes.46.4.557

  6. Hani, E H

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  7. Hansen, L

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  8. Hansen, T

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  9. Hartmann, R

    • Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes April 1997 46:565-571; doi:10.2337/diabetes.46.4.565

  10. Hartmann, U

    • Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes April 1997 46:565-571; doi:10.2337/diabetes.46.4.565

  11. Hattersley, A T

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

  12. Heikkinen, S

    • The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes April 1997 46:711-712

  13. Hill, N J

    • Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes April 1997 46:695-700; doi:10.2337/diabetes.46.4.695

  14. Holst, J J

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  15. Hosoi, M

    • Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes April 1997 46:682-687; doi:10.2337/diabetes.46.4.682

I

  1. Igwe, R

    • Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes April 1997 46:659-664; doi:10.2337/diabetes.46.4.659

  2. Inoue, H

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  3. Iynedjian, P B

    • Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes April 1997 46:622-631; doi:10.2337/diabetes.46.4.622

J

  1. Jeanrenaud, B

    • Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes April 1997 46:717-719; doi:10.2337/diabetes.46.4.717

  2. Johnson, W T

    • Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes April 1997 46:637-642; doi:10.2337/diabetes.46.4.637

K

  1. Kaisaki, P J

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

  2. Kantele, J M

    • Glutamate decarboxylase-reactive peripheral blood lymphocytes from patients with IDDM express gut-specific homing receptor alpha4beta7-integrin. Diabetes April 1997 46:583-588; doi:10.2337/diabetes.46.4.583

  3. Karges, W

    • Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk-based IDDM prevention trial. Diabetes April 1997 46:557-564; doi:10.2337/diabetes.46.4.557

  4. Kautzky-Willer, A

    • Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes April 1997 46:607-614; doi:10.2337/diabetes.46.4.607

  5. Kawagishi, T

    • Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes April 1997 46:682-687; doi:10.2337/diabetes.46.4.682

  6. Kekäläinen, P

    • The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes April 1997 46:711-712

  7. Kemp, D

    • Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk-based IDDM prevention trial. Diabetes April 1997 46:557-564; doi:10.2337/diabetes.46.4.557

  8. Kinder, S J

    • Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes April 1997 46:572-582; doi:10.2337/diabetes.46.4.572

  9. Kleemann, R

    • Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats: dose, timing, early effect on islet area, and switch in infiltrate from Th1 to Th2 cells. Diabetes April 1997 46:589-598; doi:10.2337/diabetes.46.4.589

  10. Klemetti, P

    • Glutamate decarboxylase-reactive peripheral blood lymphocytes from patients with IDDM express gut-specific homing receptor alpha4beta7-integrin. Diabetes April 1997 46:583-588; doi:10.2337/diabetes.46.4.583

  11. Knowler, W C

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  12. Kogawa, K

    • Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes April 1997 46:682-687; doi:10.2337/diabetes.46.4.682

  13. Kolb, H

    • Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats: dose, timing, early effect on islet area, and switch in infiltrate from Th1 to Th2 cells. Diabetes April 1997 46:589-598; doi:10.2337/diabetes.46.4.589

  14. Kriauciunas, A

    • Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes April 1997 46:637-642; doi:10.2337/diabetes.46.4.637

  15. Kuusisto, J

    • The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes April 1997 46:711-712

L

  1. Laakso, M

    • The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes April 1997 46:711-712

  2. Lawrence, J C, Jr

    • New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes April 1997 46:541-547; doi:10.2337/diabetes.46.4.541

  3. Levy, E R

    • Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes April 1997 46:695-700; doi:10.2337/diabetes.46.4.695

  4. Linares, A

    • Anti-insulin activity in normal newborn cord-blood serum: absence of IgG-mediated insulin binding. Diabetes April 1997 46:713-716; doi:10.2337/diabetes.46.4.713

  5. Longo, F M

    • Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Diabetes April 1997 46:647-652; doi:10.2337/diabetes.46.4.647

  6. Lord, C J

    • Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes April 1997 46:695-700; doi:10.2337/diabetes.46.4.695

  7. Ludvik, B

    • Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes April 1997 46:607-614; doi:10.2337/diabetes.46.4.607

  8. Lyons, P A

    • Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes April 1997 46:695-700; doi:10.2337/diabetes.46.4.695

M

  1. Mackie, A D

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

  2. Maekawa, K

    • Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes April 1997 46:682-687; doi:10.2337/diabetes.46.4.682

  3. Manetta, J

    • Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes April 1997 46:637-642; doi:10.2337/diabetes.46.4.637

  4. Maser, R E

    • Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes April 1997 46:665-670; doi:10.2337/diabetes.46.4.665

  5. Mizisin, A P

    • Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Diabetes April 1997 46:647-652; doi:10.2337/diabetes.46.4.647

  6. Modler, H W

    • Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats: dose, timing, early effect on islet area, and switch in infiltrate from Th1 to Th2 cells. Diabetes April 1997 46:589-598; doi:10.2337/diabetes.46.4.589

  7. Molina, P E

    • Renal glucose production during insulin-induced hypoglycemia. Diabetes April 1997 46:643-646; doi:10.2337/diabetes.46.4.643

  8. Morii, H

    • Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes April 1997 46:682-687; doi:10.2337/diabetes.46.4.682

  9. Mullane, J

    • Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes April 1997 46:632-636; doi:10.2337/diabetes.46.4.632

  10. Muller, D C

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  11. Myers, S R

    • Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes April 1997 46:637-642; doi:10.2337/diabetes.46.4.637

  12. Møller, A M

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

N

  1. Nishizawa, Y

    • Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes April 1997 46:682-687; doi:10.2337/diabetes.46.4.682

  2. North, M

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  3. Nowotny, P

    • Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes April 1997 46:607-614; doi:10.2337/diabetes.46.4.607

O

  1. O'Reilly, L A

    • alpha-Cell neogenesis in an animal model of IDDM. Diabetes April 1997 46:599-606; doi:10.2337/diabetes.46.4.599

  2. Okuno, Y

    • Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes April 1997 46:682-687; doi:10.2337/diabetes.46.4.682

  3. Orchard, T J

    • Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes April 1997 46:665-670; doi:10.2337/diabetes.46.4.665

P

  1. Pacini, G

    • Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes April 1997 46:607-614; doi:10.2337/diabetes.46.4.607

  2. Pambianco, G

    • Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes April 1997 46:665-670; doi:10.2337/diabetes.46.4.665

  3. Paronen, J

    • Glutamate decarboxylase-reactive peripheral blood lymphocytes from patients with IDDM express gut-specific homing receptor alpha4beta7-integrin. Diabetes April 1997 46:583-588; doi:10.2337/diabetes.46.4.583

  4. Pedersen, O

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  5. Perheentupa, J

    • Glutamate decarboxylase-reactive peripheral blood lymphocytes from patients with IDDM express gut-specific homing receptor alpha4beta7-integrin. Diabetes April 1997 46:583-588; doi:10.2337/diabetes.46.4.583

  6. Permutt, M A

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  7. Peterson, J

    • Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes April 1997 46:632-636; doi:10.2337/diabetes.46.4.632

  8. Peterson, L B

    • Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes April 1997 46:695-700; doi:10.2337/diabetes.46.4.695

  9. Pettitt, D J

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  10. Philippe, J

    • Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes April 1997 46:622-631; doi:10.2337/diabetes.46.4.622

  11. Philippi, A

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  12. Phillips, J M

    • alpha-Cell neogenesis in an animal model of IDDM. Diabetes April 1997 46:599-606; doi:10.2337/diabetes.46.4.599

  13. Phillips, S

    • Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes April 1997 46:671-681; doi:10.2337/diabetes.46.4.671

  14. Pihlajamäki, J

    • The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes April 1997 46:711-712

  15. Podolin, P L

    • Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes April 1997 46:695-700; doi:10.2337/diabetes.46.4.695

  16. Prager, R

    • Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes April 1997 46:607-614; doi:10.2337/diabetes.46.4.607

  17. Pye, W S

    • Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model. Diabetes April 1997 46:548-556; doi:10.2337/diabetes.46.4.548

R

  1. Rabensteiner, D

    • Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes April 1997 46:607-614; doi:10.2337/diabetes.46.4.607

  2. Radziuk, J M

    • Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model. Diabetes April 1997 46:548-556; doi:10.2337/diabetes.46.4.548

  3. Ram, J L

    • Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes April 1997 46:659-664; doi:10.2337/diabetes.46.4.659

  4. Rasmussen, S K

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  5. Richter, W

    • Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes April 1997 46:565-571; doi:10.2337/diabetes.46.4.565

  6. Rissanen, J

    • The Ala54Thr polymorphism of the fatty acid binding protein 2 gene does not influence insulin sensitivity in Finnish nondiabetic and NIDDM subjects. Diabetes April 1997 46:711-712

  7. Roach, P J

    • New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes April 1997 46:541-547; doi:10.2337/diabetes.46.4.541

  8. Rohner-Jeanrenaud, F

    • Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes April 1997 46:717-719; doi:10.2337/diabetes.46.4.717

  9. Rouard, M

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  10. Rowsell, P

    • Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats: dose, timing, early effect on islet area, and switch in infiltrate from Th1 to Th2 cells. Diabetes April 1997 46:589-598; doi:10.2337/diabetes.46.4.589

  11. Ruiz, J

    • Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes April 1997 46:622-631; doi:10.2337/diabetes.46.4.622

S

  1. Sainsbury, A

    • Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes April 1997 46:717-719; doi:10.2337/diabetes.46.4.717

  2. Sarvetnick, N

    • alpha-Cell neogenesis in an animal model of IDDM. Diabetes April 1997 46:599-606; doi:10.2337/diabetes.46.4.599

  3. Savilahti, E

    • Glutamate decarboxylase-reactive peripheral blood lymphocytes from patients with IDDM express gut-specific homing receptor alpha4beta7-integrin. Diabetes April 1997 46:583-588; doi:10.2337/diabetes.46.4.583

  4. Schmetterer, L

    • Nitric oxide and ocular blood flow in patients with IDDM. Diabetes April 1997 46:653-658; doi:10.2337/diabetes.46.4.653

  5. Scollay, R

    • Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes April 1997 46:572-582; doi:10.2337/diabetes.46.4.572

  6. Scott, F W

    • Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats: dose, timing, early effect on islet area, and switch in infiltrate from Th1 to Th2 cells. Diabetes April 1997 46:589-598; doi:10.2337/diabetes.46.4.589

  7. Shibuya, N

    • Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk-based IDDM prevention trial. Diabetes April 1997 46:557-564; doi:10.2337/diabetes.46.4.557

  8. Shields, J E

    • Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model. Diabetes April 1997 46:548-556; doi:10.2337/diabetes.46.4.548

  9. Shoji, T

    • Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes April 1997 46:682-687; doi:10.2337/diabetes.46.4.682

  10. Song, J

    • Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes April 1997 46:659-664; doi:10.2337/diabetes.46.4.659

  11. Sorkin, J D

    • Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes April 1997 46:701-710; doi:10.2337/diabetes.46.4.701

  12. Sowers, J R

    • Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes April 1997 46:659-664; doi:10.2337/diabetes.46.4.659

  13. Spinas, G A

    • Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes April 1997 46:622-631; doi:10.2337/diabetes.46.4.622

  14. Strenn, K

    • Nitric oxide and ocular blood flow in patients with IDDM. Diabetes April 1997 46:653-658; doi:10.2337/diabetes.46.4.653

  15. Studer, R K

    • Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes April 1997 46:671-681; doi:10.2337/diabetes.46.4.671

T

  1. Thomaseth, K

    • Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes April 1997 46:607-614; doi:10.2337/diabetes.46.4.607

  2. Thompson, R G

    • Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes April 1997 46:632-636; doi:10.2337/diabetes.46.4.632

  3. Tiercy, J M

    • Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes April 1997 46:622-631; doi:10.2337/diabetes.46.4.622

  4. Tinsley, F C

    • Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes April 1997 46:637-642; doi:10.2337/diabetes.46.4.637

  5. Todd, J A

    • Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes April 1997 46:695-700; doi:10.2337/diabetes.46.4.695

U

  1. Urhammer, S A

    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  2. Urrutia, I

    • Anti-insulin activity in normal newborn cord-blood serum: absence of IgG-mediated insulin binding. Diabetes April 1997 46:713-716; doi:10.2337/diabetes.46.4.713

V

  1. Vaarala, O

    • Glutamate decarboxylase-reactive peripheral blood lymphocytes from patients with IDDM express gut-specific homing receptor alpha4beta7-integrin. Diabetes April 1997 46:583-588; doi:10.2337/diabetes.46.4.583

  2. Vaxillaire, M

    • Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes April 1997 46:622-631; doi:10.2337/diabetes.46.4.622
    • Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes April 1997 46:726-730; doi:10.2337/diabetes.46.4.726

  3. Velho, G

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  4. Vionnet, N

    • Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes April 1997 46:688-694; doi:10.2337/diabetes.46.4.688

  5. Visconti, M

    • Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk-based IDDM prevention trial. Diabetes April 1997 46:557-564; doi:10.2337/diabetes.46.4.557

W

  1. Waldhäusl, W

    • Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes April 1997 46:607-614; doi:10.2337/diabetes.46.4.607

  2. Walsh, M F

    • Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes April 1997 46:659-664; doi:10.2337/diabetes.46.4.659

  3. Wicker, L S

    • Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes April 1997 46:695-700; doi:10.2337/diabetes.46.4.695

  4. Wiest-Ladenburger, U

    • Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes April 1997 46:565-571; doi:10.2337/diabetes.46.4.565

  5. Williams, V K

    • Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes April 1997 46:637-642; doi:10.2337/diabetes.46.4.637

  6. Wöerz-Pagenstert, U

    • Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats: dose, timing, early effect on islet area, and switch in infiltrate from Th1 to Th2 cells. Diabetes April 1997 46:589-598; doi:10.2337/diabetes.46.4.589

  7. Wolzt, M

    • Nitric oxide and ocular blood flow in patients with IDDM. Diabetes April 1997 46:653-658; doi:10.2337/diabetes.46.4.653

Y

  1. Yakubu-Madus, F E

    • Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes April 1997 46:637-642; doi:10.2337/diabetes.46.4.637

  2. Yamagata, K

    • Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes April 1997 46:720-725; doi:10.2337/diabetes.46.4.720

Z

  1. Zahnd, G

    • Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes April 1997 46:622-631; doi:10.2337/diabetes.46.4.622

  2. Zakrzewska, K E

    • Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes April 1997 46:717-719; doi:10.2337/diabetes.46.4.717

Current Issue

  1. February 2012, 61 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes
Advertisement